Search

Your search keyword '"Abella, Eugenia"' showing total 321 results

Search Constraints

Start Over You searched for: Author "Abella, Eugenia" Remove constraint Author: "Abella, Eugenia"
321 results on '"Abella, Eugenia"'

Search Results

1. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

3. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

4. Chronic lymphocytic leukemia–like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia

5. Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma

6. Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy

11. Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes

12. Do Patients and Physicians Agree When They Assess Quality of Life?

13. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid

14. Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

15. Genetic and phenotypic characterisation of HIV ‐associated aggressive B‐cell non‐Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications

16. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

17. P-203: Early mortality and treatment discontinuation in multiple myeloma patients treated in front-line with bortezomib, lenalidomide and dexamethasone (VRD)

20. Cross-sectional study to assess the efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies

22. Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.

23. Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin’s lymphoma in Spain

27. Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results

35. Single‐agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study

36. Reduced Expression of the CD94/NKG2C NK Cell Receptor in Chronic Lymphocytic Leukemia (CLL) and CLL-like Monoclonal B-Cell Lymphocytosis (MBL)

37. Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia

38. Deciphering the CXCL9-CXCL10-CXCL11/CXCR3 Axis in CLL-like Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia: A New Target for Immune Activation?

39. New factors involved in the appearance of Mandibular Osteonecrosis by Bisphosphonates in Multiple Myeloma. A multicentric study.

40. Prescription Patterns and Outcomes of First-Line Therapy for Non-Transplant Eligible Multiple Myeloma Real-Life Patients According to Age: A Retrospective Analysis of the 2012-2016 Period

42. Anthracycline‐induced cardiotoxicity in diffuse large B‐cell lymphoma: NT‐proBNP and cardiovascular score for risk stratification

47. Single‐agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study.

48. Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma

49. Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL

50. Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group.

Catalog

Books, media, physical & digital resources